Articles

Glick support boosts IU eye research

A $10 million research endowment at the Eugene and Marilyn Glick Eye Institute has attracted seven new researchers to the Indiana University School of Medicine’s Ophthalmology Department.

Read More

Health care VC slows in 2011

Four Hoosier companies attracted more than $10.5 million, down from 10 companies that attracted $18.5 million during the first half of 2010.

Read More

Zimmer playing hardball with plaintiffs’ lawyers

The Warsaw-based company has sued seven law firms this year and sent warning letters to at least three more, saying their ads and Internet postings distorted the safety record of its $1.8 billion-a-year knee business.

Read More

Indiana life sciences leaders look toward the future

Former Eli Lilly and Co. vice president Richard Dimarchi, BioCrossroads President David Johnson, angel investor Oscar Moralez and Purdue University Senior Vice President Alan Rebar discuss issues ranging from the depth of the life sciences industry in Indiana to venture capital and Purdue’s Discovery Park.

Read More

More life sciences firms opt to launch products in Europe

The U.S. Food and Drug Administration’s growing reputation for unpredictability is spurring some Indianapolis companies to join counterparts elsewhere and introduce products in Europe. The upshot is that some Americans may never benefit from innovations occurring in their backyards.

Read More

Lilly loses bid to end revived Zyprexa U.K. patent case

The High Court in London on Tuesday denied Lilly’s request for a judgment without trial against Neopharma Ltd., the closely held company that has European marketing rights for the generic version of the drug known chemically as olanzapine.

Read More

Timing good for 2-in-1 biotech drugs

Eli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the world’s most successful biotech medicines, which are about to see their patents expire.

Read More

Q&A

Vi Shukla is a scientific leader at Indianapolis-based Dow AgroSciences LLC, focused on its Exzact Precision Technology tools for genetic engineering of plants and crops. Dow Agro used the technology in its own crop seed products, and has also been licensing for use in tomatos and trees.

Read More